Don’t miss the Life Science Barometer 2022

Now is the time! Through the Life Science Barometer 2022, we map the Swedish life science industry and highlight needs and trends in the industry. The results will be presented in the next edition of the SwedenBIO pipeline report published in February 2023 - and our member companies will get a preview at the SwedenBIO Summit already in December.

This is the fun of working on SwedenBIO’s new Life Science Barometer 2022 survey.

We offer you the most up-to-date and relevant statistics on the market, and you enable this important work by responding to the survey. Help us provide you with the best possible data by answering the questions – and feel free to encourage more companies to respond!

We have sent out personal invitations to the survey to SwedenBIO members and all companies involved in drug development in Sweden. However, all life science companies are welcome to respond via this link: Life Science Barometer 2022.

The survey takes about 5-10 minutes to complete. We need one response per company, from a person with strategic management responsibility over the company, preferably the CEO. You can reply on your smartphone or computer. You can pause whenever you wish to continue later. We would like to receive your response as soon as possible, but no later than 21 October 2022.

What do we aim to tell you?

With your contribution, we can answer questions such as:

  • What is the distribution of company sizes in the sector?
  • Which sub-segment of the life sciences industry brings together the most staff?
  • What percentage of companies started in a different field of activity than they are currently in?
  • How international are Swedish life science companies in terms of management, employees and operations?
  • Do conditions for clinical trials differ between pharma and medtech companies?
  • What factors do companies think will affect their business in 2023?

We also conduct in-depth information collection on Sweden’s pharmaceutical pipeline (outside the survey) to answer questions such as:

  • How has the distribution of projects focusing on small molecules relative to biomolecules evolved over time?
  • How does the focus on therapeutic areas differ between Swedish pharmaceutical companies and large international companies?
  • What happened to the drug candidates that were in Phase III in 2020? Which ones were closed? Which ones are on the market now?
  • How has the pandemic affected Sweden’s pharmaceutical pipeline?